At the molecular level, 5-amino-1MQ functions as a competitive inhibitor of NNMT, demonstrating remarkable potency with an IC of 1.2 0.1 M under standard assay conditions (50 M SAM, 100 M nicotinic acid). This represents a dramatic 10-fold improvement over the parent compound 1-methylquinolinium, achieved through strategic amino group substitution that enhances binding affinity to the NNMT active site. The compound's mechanism centers on preventing the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), thereby preserving nicotinamide for recycling back to NAD+ through the salvage pathway. This intervention effectively blocks what researchers have termed the "NNMT metabolic drain" a process that simultaneously depletes NAD+ precursors and consumes cellular methylation capacity
GHK-Cu, BPC-157, TB-500, and KPV are four individual peptides of this stack, each having well-studied, unique mechanisms of action
The discrepancy between demonstrated subcutaneous efficacy (or lack thereof) and marketed oral supplements creates a fundamental problem: commercially available AOD-9604 supplements likely deliver negligible systemic peptide due to oral bioavailability limitations
But there are many other kinds of peptides in our bodies, Dr
When should the 96365 CPT code be used instead of IV push or hydration codes
